youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
IPN:EPA
Ipsen SA
€147.60
arrow_downward
-0.94%(-1.40) 1D
Oct 19, 4:53:55 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IPN...
Open
€150.20
High
€150.20
Low
€146.90
Mkt. cap
12.38B
Avg. vol.
106.72K
Volume
15.51K
P/E ratio
23.92
52-wk high
€174.00
52-wk low
€112.70
EPS
€6.18
Shares outstanding
83.81M
No. of employees
6K
Open
€150.20
High
€150.20
Low
€146.90
Mkt. cap
12.38B
Avg. vol.
106.72K
Volume
15.51K
P/E ratio
23.92
52-wk high
€174.00
52-wk low
€112.70
EPS
€6.18
Shares outstanding
83.81M
No. of employees
6K
News stories
From web sources and news partners
BigGo Finance
·
46 minutes ago
S&P 500, Nasdaq Climb at Open as AI Stocks Rebound; Dow Slips
RealMoney Pro
·
41 minutes ago
Charting the Markets: The S&P Is Still Bullish. But for How Long?
GuruFocus
·
44 minutes ago
Bank of America Securities Upgrades Dow Inc. (DOW) to Neutral on Rising Chemical Prices
TradingView
·
1 hour ago
The Dow Jones Index Opens 0.08% Lower
Profile
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
About Ipsen SA